

Helge Taubert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6739045/publications.pdf>

Version: 2024-02-01

142
papers

7,642
citations

94269

37
h-index

58464

82
g-index

145
all docs

145
docs citations

145
times ranked

10778
citing authors

#	ARTICLE	IF	CITATIONS
1	Utility of stromal tumor infiltrating lymphocyte scoring (sTILs) for risk stratification of patients with muscle-invasive urothelial bladder cancer after radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 63.e19-63.e26.	0.8	6
2	Reduced Recurrence Rates Are Associated with Photodynamic Diagnostics Compared to White Light after Extended Transurethral Resection of Bladder Tumors. <i>Life</i> , 2022, 12, 641.	1.1	0
3	Combined miR-486 and GP88 (Progranulin) Serum Levels Are Suggested as Supportive Biomarkers for Therapy Decision in Elderly Prostate Cancer Patients. <i>Life</i> , 2022, 12, 732.	1.1	1
4	Immune Cell-Associated Protein Expression Helps to Predict Survival in Muscle-Invasive Urothelial Bladder Cancer Patients after Radical Cystectomy and Optional Adjuvant Chemotherapy. <i>Cells</i> , 2021, 10, 159.	1.8	6
5	TERT Promoter Mutation Analysis of Whole-Organ Mapping Bladder Cancers. <i>Genes</i> , 2021, 12, 230.	1.0	10
6	GP88/PGRN Serum Levels Are Associated with Prognosis for Oral Squamous Cell Carcinoma Patients. <i>Biology</i> , 2021, 10, 400.	1.3	4
7	Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer Patients. <i>Cancers</i> , 2021, 13, 2327.	1.7	8
8	Serum miRNAs Support the Indication for MRI-Ultrasound Fusion-Guided Biopsy of the Prostate in Patients with Low-PI-RADS Lesions. <i>Cells</i> , 2021, 10, 1315.	1.8	4
9	High Androgen Receptor mRNA Expression Is Associated with Improved Outcome in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer. <i>Life</i> , 2021, 11, 642.	1.1	3
10	Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor Therapy. <i>Urology</i> , 2021, 157, 93-101.	0.5	6
11	Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer Patients. <i>Cells</i> , 2021, 10, 1796.	1.8	3
12	Prognostic impact of molecular muscle-invasive bladder cancer subtyping approaches and correlations with variant histology in a population-based mono-institutional cystectomy cohort. <i>World Journal of Urology</i> , 2021, 39, 4011-4019.	1.2	22
13	The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 6567-6578.	0.9	10
14	Analysis of tripartite motif (TRIM) family gene expression in prostate cancer bone metastases. <i>Carcinogenesis</i> , 2021, 42, 1475-1484.	1.3	5
15	Bladder Tumor Subtype Commitment Occurs in Carcinoma <i>in Situ</i> Driven by Key Signaling Pathways Including ECM Remodeling. <i>Cancer Research</i> , 2021, 81, 1552-1566.	0.4	26
16	Cell-Free DNA Variant Sequencing Using Plasma and AR-V7 Testing of Circulating Tumor Cells in Prostate Cancer Patients. <i>Cells</i> , 2021, 10, 3223.	1.8	4
17	RNA Sequencing of Collecting Duct Renal Cell Carcinoma Suggests an Interaction between miRNA and Target Genes and a Predominance of Deregulated Solute Carrier Genes. <i>Cancers</i> , 2020, 12, 64.	1.7	18
18	Analysis of CXCL9, PD1 and PD-L1 mRNA in Stage T1 Non-Muscle Invasive Bladder Cancer and Their Association with Prognosis. <i>Cancers</i> , 2020, 12, 2794.	1.7	17

#	ARTICLE	IF	CITATIONS
19	PIWI-Like 1 and PIWI-Like 2 Expression in Breast Cancer. <i>Cancers</i> , 2020, 12, 2742.	1.7	4
20	Nanoparticle-complexed anti-miRs for inhibiting tumor growth and metastasis in prostate carcinoma and melanoma. <i>Journal of Nanobiotechnology</i> , 2020, 18, 173.	4.2	17
21	Expression of AR-V7 (Androgen Receptor Variant 7) Protein in Granular Cytoplasmic Structures Is an Independent Prognostic Factor in Prostate Cancer Patients. <i>Cancers</i> , 2020, 12, 2639.	1.7	5
22	MiR-155-5p and MiR-203a-3p Are Prognostic Factors in Soft Tissue Sarcoma. <i>Cancers</i> , 2020, 12, 2254.	1.7	9
23	CCL2 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Shows Divergent Prognostic Potential for Bladder Cancer Patients Depending on Lymph Node Stage. <i>Cancers</i> , 2020, 12, 1253.	1.7	21
24	Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy. , 2020, 8, e000162.		45
25	Causes and Consequences of A Glutamine Induced Normoxic HIF1 Activity for the Tumor Metabolism. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4742.	1.8	19
26	Investigation of the Prognostic Role of Carbonic Anhydrase 9 (CAIX) of the Cellular mRNA/Protein Level or Soluble CAIX Protein in Patients with Oral Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 375.	1.8	20
27	Expression of PD-1 and CTLA-4 Are Negative Prognostic Markers in Renal Cell Carcinoma. <i>Journal of Clinical Medicine</i> , 2019, 8, 743.	1.0	29
28	Co-staining of microRNAs and their target proteins by miRNA in situ hybridization and immunohistofluorescence on prostate cancer tissue microarrays. <i>Laboratory Investigation</i> , 2019, 99, 1527-1534.	1.7	13
29	The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes. <i>Cancer Immunology Research</i> , 2019, 7, 923-938.	1.6	148
30	Exploring the MIR143-UPAR Axis for the Inhibition of Human Prostate Cancer Cells InÂVitro and InÂVivo. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 16, 272-283.	2.3	17
31	Prognostic impact of mRNA levels of LGR5 transcript variants in OSCC patients. <i>BMC Cancer</i> , 2019, 19, 155.	1.1	7
32	Piwi-like 1 protein expression is a prognostic factor for renal cell carcinoma patients. <i>Scientific Reports</i> , 2019, 9, 1741.	1.6	11
33	Expression of GP88 (Progranulin) Protein Is an Independent Prognostic Factor in Prostate Cancer Patients. <i>Cancers</i> , 2019, 11, 2029.	1.7	9
34	Molecular Composition of Genomic <i>TMPRSS2-ERG</i> Rearrangements in Prostate Cancer. <i>Disease Markers</i> , 2019, 2019, 1-8.	0.6	8
35	Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. <i>European Journal of Cancer</i> , 2019, 106, 234-243.	1.3	75
36	A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy. <i>Oncotarget</i> , 2018, 9, 15001-15014.	0.8	33

#	ARTICLE	IF	CITATIONS
37	Piwi-like 1 and -2 protein expression levels are prognostic factors for muscle invasive urothelial bladder cancer patients. <i>Scientific Reports</i> , 2018, 8, 17693.	1.6	17
38	Low HIF-1 α and low EGFR mRNA Expression Significantly Associate with Poor Survival in Soft Tissue Sarcoma Patients; the Proteins React Differently. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3842.	1.8	8
39	Expression of GP88 (progranulin) in serum of prostate cancer patients is associated with Gleason scores and overall survival. <i>Cancer Management and Research</i> , 2018, Volume 10, 4173-4180.	0.9	13
40	Elevated HERV-K Expression in Soft Tissue Sarcoma Is Associated with Worsened Relapse-Free Survival. <i>Frontiers in Microbiology</i> , 2018, 9, 211.	1.5	23
41	Cytotoxicity of AMANTADIG – a semisynthetic digitoxigenin derivative – alone and in combination with docetaxel in human hormone-refractory prostate cancer cells and its effect on Na ⁺ /K ⁺ -ATPase inhibition. <i>Biomedicine and Pharmacotherapy</i> , 2018, 107, 464-474.	2.5	13
42	Serum levels of miR-320 family members are associated with clinical parameters and diagnosis in prostate cancer patients. <i>Oncotarget</i> , 2018, 9, 10402-10416.	0.8	44
43	Normoxic accumulation of HIF1 α is associated with glutaminolysis. <i>Clinical Oral Investigations</i> , 2017, 21, 211-224.	1.4	27
44	Differences in the frequencies of HLA-class I and II alleles between German patients with renal cell carcinoma and healthy controls. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 565-571.	2.0	5
45	Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. <i>Cell</i> , 2017, 171, 540-556.e25.	13.5	1,742
46	Differential prognostic value of MYC immunohistochemistry in subtypes of papillary renal cell carcinoma. <i>Scientific Reports</i> , 2017, 7, 16424.	1.6	11
47	P4HA1: A single-gene surrogate of hypoxia signatures in oral squamous cell carcinoma patients. <i>Clinical and Translational Radiation Oncology</i> , 2017, 5, 6-11.	0.9	21
48	Salivary miR-93 and miR-200a as post-radiotherapy biomarkers in head and neck squamous cell carcinoma. <i>Oncology Reports</i> , 2017, 38, 1268-1275.	1.2	36
49	Analysis of Argonaute Complex Bound mRNAs in DU145 Prostate Carcinoma Cells Reveals New miRNA Target Genes. <i>Prostate Cancer</i> , 2017, 2017, 1-12.	0.4	3
50	CMG2 Expression Is an Independent Prognostic Factor for Soft Tissue Sarcoma Patients. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2648.	1.8	14
51	A new semisynthetic cardenolide analog 3 β -[2-(1-amantadine)-1-on-ethylamine]-digitoxigenin (AMANTADIG) affects G2/M cell cycle arrest and miRNA expression profiles and enhances proapoptotic survivin-2B expression in renal cell carcinoma cell lines. <i>Oncotarget</i> , 2017, 8, 11676-11691.	0.8	18
52	MiRNA-21 Expression Decreases from Primary Tumors to Liver Metastases in Colorectal Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0148580.	1.1	15
53	miR-199a-5p regulates HIF-1 α and OSGIN2 and its expression is correlated to soft-tissue sarcoma patients' outcome. <i>Oncology Letters</i> , 2016, 12, 5281-5288.	0.8	16
54	HLA-E expression and its clinical relevance in human renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 67360-67372.	0.8	38

#	ARTICLE	IF	CITATIONS
55	Piwi 2 Expression Is Correlated with Disease-Specific and Progression-Free Survival of Chemotherapy-Treated Bladder Cancer Patients. <i>Molecular Medicine</i> , 2015, 21, 371-380.	1.9	21
56	The combined serum levels of <i>miR-375</i> and urokinase plasminogen activator receptor are suggested as diagnostic and prognostic biomarkers in prostate cancer. <i>International Journal of Cancer</i> , 2015, 137, 1406-1416.	2.3	45
57	Targeting of EGFR and HER2 with therapeutic antibodies and siRNA. <i>Strahlentherapie Und Onkologie</i> , 2015, 191, 180-191.	1.0	22
58	Clinical relevance of miR-mediated HLA-G regulation and the associated immune cell infiltration in renal cell carcinoma. <i>Oncolmmunology</i> , 2015, 4, e1008805.	2.1	58
59	The New Semisynthetic Cardenolide Analog 3 ^Î -[2-(1-Amantadine)-1-on-ethylamine]-digitoxigenin (AMANTADIG) Efficiently Suppresses Cell Growth in Human Leukemia and Urological Tumor Cell Lines. <i>Anticancer Research</i> , 2015, 35, 5271-5.	0.5	5
60	Betulinic Acid Derivatives NVX-207 and B10 for Treatment of Glioblastoma—An in Vitro Study of Cytotoxicity and Radiosensitization. <i>International Journal of Molecular Sciences</i> , 2014, 15, 19777-19790.	1.8	30
61	Association of Tissue mRNA and Serum Antigen Levels of Members of the Urokinase-Type Plasminogen Activator System with Clinical and Prognostic Parameters in Prostate Cancer. <i>BioMed Research International</i> , 2014, 2014, 1-9.	0.9	16
62	Comparative genomic hybridization shows complex genomic changes of plasmacytoid urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1234-1239.	0.8	6
63	High coexpression of <i>CCL2</i> and <i>CX3CL1</i> is gender-specifically associated with good prognosis in soft tissue sarcoma patients. <i>International Journal of Cancer</i> , 2014, 135, 2096-2106.	2.3	23
64	Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis. <i>BMC Cancer</i> , 2014, 14, 974.	1.1	13
65	Piwi-like 1 and 4 gene transcript levels are associated with clinicopathological parameters in renal cell carcinomas. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 686-690.	1.8	30
66	Comparative microRNA Profiling of Prostate Carcinomas with Increasing Tumor Stage by Deep Sequencing. <i>Molecular Cancer Research</i> , 2014, 12, 250-263.	1.5	75
67	Inverse prognostic impact of ErbB2 mRNA and protein expression level in tumors of soft tissue sarcoma patients. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 912-918.	1.0	7
68	Identification of ZNF217, hnRNP κ , VEGF β and IPO7 as targets for microRNAs that are downregulated in prostate carcinoma. <i>International Journal of Cancer</i> , 2013, 132, 775-784.	2.3	70
69	Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy. <i>BMC Cancer</i> , 2013, 13, 71.	1.1	74
70	SNAI1 Protein Expression is an Independent Negative Prognosticator in Muscle-Invasive Bladder Cancer. <i>Annals of Surgical Oncology</i> , 2013, 20, 3669-3674.	0.7	11
71	Nuclear E-cadherin Expression is Associated with the Loss of Membranous E-cadherin, Plasmacytoid Differentiation and Reduced Overall Survival in Urothelial Carcinoma of the Bladder. <i>Annals of Surgical Oncology</i> , 2013, 20, 2440-2445.	0.7	32
72	Impact of expression of the uPA system in sarcomas. <i>Biomarkers in Medicine</i> , 2013, 7, 473-480.	0.6	7

#	ARTICLE	IF	CITATIONS
73	Lack of evidence for frequent <i>scp>MED12</scp></i> p. <i>scp>L1224F</scp></i> mutation in prostate tumours from Caucasian patients. <i>Journal of Pathology</i> , 2013, 230, 453-456.	2.1	8
74	The protooncogene <i>scp>ERG</scp></i> is a target of micro <i>scp>RNA </scp></i> <i>miRâ€145</i> in prostate cancer. <i>FEBS Journal</i>, 2013, 280, 2105-2116.</i>	2.2	56
75	A RASSF1A Polymorphism Restricts p53/p73 Activation and Associates with Poor Survival and Accelerated Age of Onset of Soft Tissue Sarcoma. <i>Cancer Research</i> , 2012, 72, 2206-2217.	0.4	42
76	Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer. <i>Cancer Research</i> , 2012, 72, 4074-4084.	0.4	58
77	The real face of HIF1Î± in the tumor process. <i>Cell Cycle</i> , 2012, 11, 3932-3936.	1.3	31
78	Prognostic impact of mRNA levels of osteopontin splice variants in soft tissue sarcoma patients. <i>BMC Cancer</i> , 2012, 12, 131.	1.1	19
79	Expression of human Piwi-like genes is associated with prognosis for soft tissue sarcoma patients. <i>BMC Cancer</i> , 2012, 12, 272.	1.1	21
80	Combined mRNA expression levels of members of the urokinase plasminogen activator (uPA) system correlate with disease-associated survival of soft-tissue sarcoma patients. <i>BMC Cancer</i> , 2011, 11, 273.	1.1	11
81	Elevated Transcript Levels From the MDM2 P1 Promoter and Low p53 Transcript Levels Are Associated With Poor Prognosis in Human Pancreatic Ductal Adenocarcinoma. <i>Pancreas</i> , 2011, 40, 265-270.	0.5	28
82	Coexpression of hypoxia-inducible factor-1Î± and glucose transporter-1 is associated with poor prognosis in oral squamous cell carcinoma patients. <i>Histopathology</i> , 2011, 58, 1136-1147.	1.6	66
83	A novel splice variant of the stem cell marker LGR5/GPR49 is correlated with the risk of tumor-related death in soft-tissue sarcoma patients. <i>BMC Cancer</i> , 2011, 11, 429.	1.1	20
84	Increased betulinic acid induced cytotoxicity and radiosensitivity in glioma cells under hypoxic conditions. <i>Radiation Oncology</i> , 2011, 6, 111.	1.2	37
85	MDM2 SNP309 Associates With Accelerated Pancreatic Adenocarcinoma Formation. <i>Pancreas</i> , 2010, 39, 76-80.	0.5	23
86	Elevated tumor and serum levels of the hypoxia-associated protein osteopontin are associated with prognosis for soft tissue sarcoma patients. <i>BMC Cancer</i> , 2010, 10, 132.	1.1	30
87	Expression of survivin detected by immunohistochemistry in the cytoplasm and in the nucleus is associated with prognosis of leiomyosarcoma and synovial sarcoma patients. <i>BMC Cancer</i> , 2010, 10, 65.	1.1	27
88	Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. <i>International Journal of Cancer</i> , 2010, 126, 73-80.	2.3	401
89	Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells. <i>Radiation Oncology</i> , 2010, 5, 82.	1.2	36
90	HIF-1Î± is a Prognostic Marker in Oral Squamous Cell Carcinomas. <i>International Journal of Biological Markers</i> , 2010, 25, 87-92.	0.7	38

#	ARTICLE	IF	CITATIONS
91	Chemosensitivity Profiles Identify Polymorphisms in the p53 Network Genes 14-3-3 β , and CD44 That Affect Sarcoma Incidence and Survival. <i>Cancer Research</i> , 2010, 70, 172-180.	0.4	45
92	Optimising the therapeutic ratio in head and neck cancer. <i>Lancet Oncology</i> , The, 2010, 11, 511-512.	5.1	3
93	HIF-1 α is a prognostic marker in oral squamous cell carcinomas. <i>International Journal of Biological Markers</i> , 2010, 25, 87-92.	0.7	21
94	A Three-Gene Signature for Outcome in Soft Tissue Sarcoma. <i>Clinical Cancer Research</i> , 2009, 15, 5191-5198.	3.2	45
95	Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Renal Cell Carcinoma Correlates with Prognosis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2190-2194.	1.1	72
96	Recent Natural Selection Identifies a Genetic Variant in a Regulatory Subunit of Protein Phosphatase 2A that Associates with Altered Cancer Risk and Survival. <i>Clinical Cancer Research</i> , 2009, 15, 6301-6308.	3.2	23
97	Prognostic Impact of HIF-1 β Expression in Patients with Definitive Radiotherapy for Cervical Cancer. <i>Strahlentherapie Und Onkologie</i> , 2008, 184, 169-174.	1.0	56
98	Immunohistochemical Detection of HIF-1 β and CAIX in Advanced Head-and-Neck Cancer. <i>Strahlentherapie Und Onkologie</i> , 2008, 184, 393-399.	1.0	38
99	Association of HDM2 Transcript Levels with Age of Onset and Prognosis in Soft Tissue Sarcomas. <i>Molecular Cancer Research</i> , 2008, 6, 1575-1581.	1.5	9
100	Frequent hypermethylation ofMST1 andMST2 in soft tissue sarcoma. <i>Molecular Carcinogenesis</i> , 2007, 46, 865-871.	1.3	144
101	Survivin protein expression and hypoxia in advanced cervical carcinoma of patients treated by radiotherapy. <i>Gynecologic Oncology</i> , 2007, 104, 139-144.	0.6	24
102	MDM2 SNP309 Accelerates Tumor Formation in a Gender-Specific and Hormone-Dependent Manner. <i>Cancer Research</i> , 2006, 66, 5104-5110.	0.4	277
103	Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: Prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1 β -related markers, and hemoglobin levels. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 1481-1487.	0.4	55
104	Elevated expression of survivin-splice variants predicts a poor outcome for soft-tissue sarcomas patients. <i>Oncogene</i> , 2005, 24, 5258-5261.	2.6	36
105	Gains of 13q are correlated with a poor prognosis in liposarcoma. <i>Modern Pathology</i> , 2005, 18, 638-644.	2.9	49
106	Alterations of cancer-related genes in soft tissue sarcomas: Hypermethylation ofRASSF1A is frequently detected in leiomyosarcoma and associated with poor prognosis in sarcoma. <i>International Journal of Cancer</i> , 2005, 114, 442-447.	2.3	50
107	Significance ofHDMX-S (orMDM4) mRNA splice variant overexpression andHDMX gene amplification on primary soft tissue sarcoma prognosis. <i>International Journal of Cancer</i> , 2005, 117, 469-475.	2.3	88
108	Detection of circulating tumor cells from renal carcinoma patients: experiences of a two-center study. <i>Oncology Reports</i> , 2005, 14, 895.	1.2	10

#	ARTICLE	IF	CITATIONS
109	Radiosensitization, after a combined treatment of survivin siRNA and irradiation, is correlated with the activation of caspases 3 and 7 in a wt-p53 sarcoma cell line, but not in a mt-p53 sarcoma cell line. <i>Oncology Reports</i> , 2005, 13, 167-72.	1.2	33
110	Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53. <i>Cancer Gene Therapy</i> , 2004, 11, 186-193.	2.2	103
111	Detection of disseminated tumor cells in peripheral blood of patients with breast cancer: correlation to nodal status and occurrence of metastases. <i>Gynecologic Oncology</i> , 2004, 92, 256-261.	0.6	34
112	A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans. <i>Cell</i> , 2004, 119, 591-602.	13.5	1,158
113	<i>MDM2</i> and Its Splice Variant Messenger RNAs: Expression in Tumors and Down-Regulation Using Antisense Oligonucleotides. <i>Molecular Cancer Research</i> , 2004, 2, 29-35.	1.5	47
114	Loss of Heterozygosity at 12q14-15 Often Occurs in Stage I Soft Tissue Sarcomas and Is Associated with MDM2 Amplification in Tumors at Various Stages. <i>Modern Pathology</i> , 2003, 16, 1109-1116.	2.9	11
115	Elevated expression level of survivin protein in soft-tissue sarcomas is a strong independent predictor of survival. <i>Clinical Cancer Research</i> , 2003, 9, 1098-104.	3.2	58
116	Isolation and enrichment of urologic tumor cells in blood samples by a semi-automated CD45 depletion autoMACS protocol. <i>International Journal of Oncology</i> , 2002, 21, 521.	1.4	12
117	Co-expression of survivin and TERT and risk of tumour-related death in patients with soft-tissue sarcoma. <i>Lancet, The</i> , 2002, 359, 943-945.	6.3	83
118	Alternative and aberrant splicing of MDM2 mRNA in human cancer. <i>Cancer Cell</i> , 2002, 2, 9-15.	7.7	182
119	High bad and bcl-xL gene expression and combined bad, bcl-xL, bax and bcl-2 mRNA levels: molecular predictors for survival of stage 2 soft tissue sarcoma patients. <i>Anticancer Research</i> , 2002, 22, 1553-9.	0.5	6
120	Low detection rate of p53 antibodies in sera of soft tissue sarcoma patients. <i>Cancer Letters</i> , 2001, 170, 199-205.	3.2	2
121	Amplification of the <i>mdm2</i> gene, but not expression of splice variants of <i>mdm2</i> mRNA, is associated with prognosis in soft tissue sarcoma. <i>International Journal of Cancer</i> , 2001, 95, 168-175.	2.3	76
122	Increased survivin transcript levels: An independent negative predictor of survival in soft tissue sarcoma patients. <i>International Journal of Cancer</i> , 2001, 95, 360-363.	2.3	86
123	Detection and enrichment of disseminated renal carcinoma cells from peripheral blood by immunomagnetic cell separation. <i>International Journal of Cancer</i> , 2001, 92, 577-582.	2.3	80
124	Cytogenetic characterization of six malignant peripheral nerve sheath tumors. <i>Cancer Genetics and Cytogenetics</i> , 2001, 128, 14-23.	1.0	36
125	A MbolI polymorphism in exon 11 of the human MDM2 gene occurring in normal blood donors and in soft tissue sarcoma patients: an indication for an increased cancer susceptibility?. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2000, 456, 39-44.	0.4	3
126	Regulation of proliferation and apoptosis in sporadic and hereditary medullary thyroid carcinomas and their putative precursor lesions. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2000, 437, 256-263.	1.4	12

#	ARTICLE	IF	CITATIONS
127	mdm2 mRNA Level is a Prognostic Factor in Soft Tissue Sarcoma. <i>Molecular Medicine</i> , 2000, 6, 50-59.	1.9	29
128	Colony formation of soft tissue sarcoma cells is inhibited by lipid-mediated antisense oligodeoxynucleotides targeting the human mdm2 oncogene. <i>Cancer Letters</i> , 2000, 149, 181-188.	3.2	14
129	High prognostic significance of Mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities. <i>Oncogene</i> , 1998, 16, 1183-1185.	2.6	77
130	Cytogenetic Characterization of Ten Malignant Fibrous Histiocytomas. <i>Cancer Genetics and Cytogenetics</i> , 1998, 100, 134-142.	1.0	16
131	No p16INK4A/CDKN2/MTS1 mutations independent of p53 status in soft tissue sarcomas. , 1998, 184, 14-17.		14
132	p53 status in radiation-induced soft-tissue sarcomas. <i>Strahlentherapie Und Onkologie</i> , 1998, 174, 427-430.	1.0	8
133	Soft Tissue Sarcomas and p53 Mutations. <i>Molecular Medicine</i> , 1998, 4, 365-372.	1.9	32
134	Prognostic Relevance of C-terminal Mdm2 Detection Is Enhanced by p53 Positivity in Soft Tissue Sarcomas. <i>Diagnostic Molecular Pathology</i> , 1997, 6, 249-254.	2.1	26
135	Immunohistochemical and clinical evaluation of cathepsin expression in soft tissue sarcomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 1997, 430, 221-225.	1.4	14
136	Prognostic value of immunohistochemistry for p53 in primary soft-tissue sarcomas: a multivariate analysis of five antibodies. <i>Journal of Cancer Research and Clinical Oncology</i> , 1997, 123, 502-508.	1.2	34
137	Prognostic value of immunohistochemistry for p53 in primary soft-tissue sarcomas: a multivariate analysis of five antibodies. <i>Journal of Cancer Research and Clinical Oncology</i> , 1997, 123, 502-508.	1.2	7
138	Frequent occurrence of p53 mutations in rhabdomyosarcoma and leiomyosarcoma, but not in fibrosarcoma and malignant neural tumors. , 1996, 69, 317-323.		38
139	Frequent occurrence of p53 mutations in rhabdomyosarcoma and leiomyosarcoma, but not in fibrosarcoma and malignant neural tumors. <i>International Journal of Cancer</i> , 1996, 69, 317-323.	2.3	1
140	Molecular and immunohistochemical p53 status in liposarcoma and malignant fibrous histiocytoma. Identification of seven new mutations for soft tissue sarcomas. <i>Cancer</i> , 1995, 76, 1187-1196.	2.0	47
141	Genetic control of cell proliferation in female germ line cells of <i>Drosophila</i> : Mosaic analysis of five discless mutations. <i>Molecular Genetics and Genomics</i> , 1987, 209, 545-551.	2.4	11
142	Growth reduction of a xenotransplanted human Soft Tissue Sarcoma by MDM2 Antisense Therapy. , 0, 2002, .		0